Related Experiment Video
Updated: Feb 10, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Insulin-like growth factor-I (lGF-l): safety and efficacy
1Endocrinology and Diabetes Research Unit, Schneider Children's Medical Center, WHO Collaborating Center for the Study of Diabetes in Youth, Tel Aviv University, Tel Aviv, Israel. laronz@clalit.org.il
Abstract:
Insulin-like growth factor I (IGF-I) is a peptide synthesized mainly in the liver by stimulation by pituitary growth hormone (GH). It circulates almost entirely bound to its binding proteins. It is the anabolic effector hormone of GH. It is the only treatment in states of GH resistance such as Laron syndrome and blocking antibodies to human GH. As it suppresses insulin and GH secretion it has been used in states of insulin resistance including Type II diabetes mellitus. IGF-I is administered by once or twice daily injections. Adverse effects are mostly caused by overdosage. The usual daily dose in children ranges from 100-200 microg/kg.
Related Concept Videos
Self-Efficacy
Survey Safety
Factors Influencing Microbial Growth: Osmolarity
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: pH
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

